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Background: Sub-Saharan Africa carries the highest HIV burden globally. It is important to understand how inter-
ventions cost-effectively fit within guidelines and implementation plans, especially in low- and middle-income
settings. We reviewed the evidence from economic evaluations of HIV prevention interventions in sub-
Saharan Africa to help inform the allocation of limited resources.
Methods:Wesearched PubMed,Web of Science, Econ-Lit, Embase, and African IndexMedicus.We included stud-
ies published between January 2009 and December 2018 reporting cost-effectiveness estimates of HIV preven-
tion interventions. We extracted health outcomes and cost-effectiveness ratios (CERs) and evaluated study
quality using the CHEERS checklist.
Findings: 60 studies met the full inclusion criteria. Prevention of mother-to-child transmission interventions had
the lowest median CERs ($1144/HIV infection averted and $191/DALY averted), while pre-exposure prophylaxis
interventions had the highest ($13,267/HIA and $799/DALY averted). Structural interventions (partner notifica-
tion, cash transfer programs) have similar CERs ($3576/HIA and $392/DALY averted) to male circumcision
($2965/HIA) and were more favourable to treatment-as-prevention interventions ($7903/HIA and $890/DALY
averted). Most interventions showed increased cost-effectiveness when prioritizing specific target groups
based on age and risk.
Interpretation: The presented cost-effectiveness information can aid policymakers and other stakeholders as they
develop guidelines and programming for HIV prevention plans in resource-constrained settings.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Sub-Saharan Africa (SSA) has experienced a large reduction in new
HIV infections over the last decade, with the number of incident infec-
tions dropping over 30% since 2010 [1]. This decrease in burden reflects
the accomplishment of a global effort focused on a region in which ap-
proximately 70% of all people living with HIV reside [2,3]. Despite this
success, the decline in incidence is slowing, and gaps in the scale-up of
HIV prevention services persist throughout SSA [3].
US$4.5 billion was allocated for HIV prevention investments in 2016
by the international community; however, a recent UNAIDS report
stated that an additional annual investment of US$7 billion is urgently
needed to meet the 2030 Sustainable Development Goals targets
[4–6]. To improve the efficiency of programming for HIV prevention,
optimizing limited financial resources is crucial to scale up high-
quality, cost-effective interventions to maximize HIV prevention [7].
In addition to evidence-based prevention tools such as voluntary
medical male circumcision (VMMC) and prevention of mother-to-
child transmission (PMTCT) strategies, new prevention methods such
asHIV pre-exposure prophylaxis (PrEP) have been heralded for their re-
markable clinical results in the reduction of HIV transmission. However,
it is important for policy- and decision-makers to identify where and
how such costly interventions fit within regional and national HIV im-
plementation plans and budgets, particularly in resource-limited coun-
tries [8].
Ascertaining the cost-effectiveness of prevention interventions is
necessary for optimal resource allocation and for identifying inefficien-
cies within prevention programs [7].
A systematic review of HIV prevention intervention cost-
effectiveness was published in 2009 by Galarraga et al., which con-
cluded that the number and quality of cost-effectiveness studies were
insufficient and too limited at that time to aid decision making and
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policy recommendations [9–10]. However, since 2009, many studies
have been published on the cost-effectiveness of various prevention in-
terventions, including newer PrEP technologies and treatment-as-
prevention [8].
No systematic review to date has evaluated these newer prevention
interventions with a focus on SSA. Such a reviewwould provide impor-
tant information on HIV prevention costs, outcomes, and effectiveness
to support policies and decision-making [8,9]. The purpose of this
review is to systematically review published analyses of the cost-
effectiveness of HIV prevention interventions in SSA settings. We aim
to 1) review evidence from studies published in the last decade that
have evaluated cost and outcome metrics for HIV prevention interven-
tions, 2) compare the costs and effects of specific prevention interven-
tions, and 3) understand the assumptions driving cost-effectiveness in
order to inform allocation of limited HIV prevention resources.
2. Methods
2.1. Search Strategy and Selection Criteria
We conducted this systematic review in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [10]. We searched PubMed/MEDLINE, Web of Sci-
ence, Econ-Lit, Embase, and African Index Medicus. Additionally, we
reviewed reference lists of retrieved articles as well as governmental
and organizational reports to complement our search. We limited stud-
ies published between January 1, 2009 and December 31, 2018. The fol-
lowing keywords were used: “HIV”; “prevention” or “control”; “cost” or
“cost-analysis” or “cost-effectiveness”; “sub-Saharan Africa”. The full
search strategy, including keywords for each database, can be found in
the supplemental material.
Inclusion criteria included full articles that were peer-reviewed and
published in English, and reported cost and outcome measures or
analysed cost-effectiveness of anHIV prevention intervention. Interven-
tions included, but were not limited to: VMMC, PMTCT, TasP, PrEP, be-
havioral interventions, vaccinations, and microbicides. As a multi-
pronged strategy, two types of PMTCT interventions were considered:
Prong II, interventions to prevent unintended pregnancies of HIV-
positive women, and Prong III, interventions providing services to re-
duce HIV transmission fromHIV-positive women to their infants. Geog-
raphy was limited to country settings within SSA, as defined by the
United Nations [11]. A full list of eligible country settings can be found
in the supplemental material. Studies that focused on HIV treatment
with no prevention aspect, systematic reviews, meta-analyses, confer-
ence abstracts, and guideline reports were excluded. Studies assessing
cost-effectiveness of an intervention's combined impact for both HIV-
positive and HIV-negative persons and studies that did not describe
costing analyses and effectiveness measures were excluded. Two re-
viewers aggregated a list of articles produced by the database search
and conducted independent screenings based on title and abstract. All
discrepancies were resolved by a third reviewer.
2.2. Quality Assessment and Data Extraction
Two reviewers independently extracted data from each of the se-
lected studies using a prepared data form, and an independent
crosscheck by a third reviewer was conducted to identify and resolve
any disagreements or uncertainties. We developed the data form
using guidance from Emory colleagues and prior systematic reviews
on similar topics. We assessed the quality of studies using the Consoli-
datedHealth Economic EvaluationReporting Standards (CHEERS) state-
ment, which contains a 24-point checklist to assess economic
evaluation studies [12].
We extracted data on intervention type, study design or model type,
geographic setting, HIV transmission method, population, intervention
description, perspective, and time horizon. Additional extracted infor-
mation included scenario descriptions, intervention effectiveness,
cost-effectiveness metric results, and discounting rates for effects and
costs. We categorized studies by prevention intervention type to com-
pare intervention-specific results. The primary measures of interest
were cost per HIV infection averted (HIA), cost per disability-adjusted
life year (DALY) averted, cost per quality-adjusted life year (QALY)
gained, and cost per life year gained (LYG). We converted study cost-
effectiveness results to 2018 US$ using the Consumer Price Index
Research in context
Evidence Before This Study
There is an increasing interest in cost-effectiveness of HIV pro-
gramming among stakeholders. The last systematic review on the
cost-effectiveness of all HIV prevention interventions was pub-
lished nearly ten years ago. At that time, cost-effectiveness studies
were limited and often unavailable for specific interventions. A
2013 systematic review presented evidence from studies specifi-
cally on pre-exposure prophylaxis and concluded that the
intervention's impact relied highly on contextual assumptions.
In the past decade, an increasing number of cost-effectiveness
studies in HIV prevention literature have become available, but
there has not yet been a single review that synthesizes the evi-
dence from all of these studies.We conducted a systematic review
for cost-effectiveness studies on HIV prevention interventions.
We searched PubMed/MEDLINE, Web of Science, Econ-Lit,
Embase, and African Index Medicus, for studies published be-
tween January 1, 2009 and December 31, 2018. Search terms in-
cluded “HIV”, “prevention” or “control”; “sub-Saharan Africa”;
“cost” or “cost-effectiveness”.
Added Value of This Study
This is the first review that provides a comprehensive and up-
date look at the cost-effectiveness of all HIV prevention interven-
tions targeted towards HIV- individuals. Additionally, this review
focuses solely on sub-Saharan Africa, the region that carries the
vast majority of the global disease burden. We show that volun-
tary medical male circumcision (VMMC) and prevention of
mother-to-child transmission (PMTCT) interventions are cost-
effective in almost all contexts. We provide evidence of cost-
effectiveness of other newer biomedical interventions, including
pre-exposure prophylaxis (PrEP) and treatment as prevention
(TasP). We hope that the evidence from this review will aid vari-
ous stakeholders, including Ministries of Health, program imple-
menters, and international donors, in their decision-making
regarding resource allocation policy for HIV prevention.
Implications of All the Available Evidence
The number of studies included in this review reflects the in-
creasing importance of considering cost-effectiveness when de-
signing or implementing HIV prevention programs in sub-
Saharan Africa. Numerous studies focused on new biomedical in-
terventions, andmany of these studies usedmathematicalmodel-
ing to provide evidence of these interventions' cost-effectiveness
since they have not yet been scaled up in sub-Saharan Africa.
However, this review shows that most interventions can be
cost-effective in specific contexts. As such, we encourage others
to use the results of this review with caution. Future economic
and costing studies onHIV prevention should includemore realis-
tic scenarios so that these data aremore accessible and relevant to
policymakers and other stakeholders.
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(CPI) Inflation Calculator and compared them to the International Mon-
etary Fund 2018 estimates of gross domestic product (GDP) per capita
for each study setting [13,14].
For each intervention type, we calculated median CERs. Separate
medians were calculated for studies reporting cost per HIA estimates
and studies reporting cost per DALY averted, QALY gained, or LYG. For
studies that explored more than one geographic setting, we considered
results from the different settings as individual estimates if they were
reported as such within a single study; these results were considered
separately when we calculated median CERs.
3. Results
We identified and screened 1115 articles, of which 146 met criteria
to be assessed for eligibility. The 969 articles thatwere initially excluded
were deemed ineligible based on the article title and abstract and did
not meet either the geographic setting or intervention criteria. Out of
the 146 articles, 60 met the full inclusion criteria (Fig. 1). These 60
peer-reviewed studies provided cost-effectiveness results for the fol-
lowing HIV prevention interventions: 14 studies on VMMC, 13 studies
on PrEP, five studies on TasP, 15 studies on PMTCT, nine studies on
other biomedical interventions, one study on behaviour change, and
three studies on structural interventions [15–74]. Among PMTCT stud-
ies, 14 considered Prong III strategies, while one focused on Prong II.
Table 1 describes characteristics of each study, including study de-
sign or model type, geographic setting, method of transmission, target
population, time horizon, HIV prevalence of the target population, per-
spective, and description of the intervention assessed. Studies focused
on heterosexual transmission among the general population except
for studies exploring prevention of mother-to-child-transmission.
Costswere predominately assessed through a healthcare payer perspec-
tive. Two studies included results from countries outside of SSA; non-
SSA results were excluded from this review [56,62].
We extracted and converted each study's reported cost-
effectiveness measure and converted them to 2018 US$. Table 2
describes these measures. Most studies provided discounted results,
with discounting ranging from 0%–5% for the base case scenario, as is
standard in cost-effectiveness literature [37]. Outcome measures were
presented as number of HIV infections averted (HIA) for a specific sce-
nario, with fewer studies reporting quality-adjusted life years (QALYs)
gained or disability-adjusted life years (DALYs) averted. A number of
studies did not provide numerical values for cost-effectiveness mea-
sures but rather stated whether an intervention was a dominant
(cost-savingswith better outcomes) or dominated (costlier with poorer
outcomes) strategy [55,58,67]. Themost cost-effective interventions in-
cluded -$8356 per HIA for a microbicide intervention in South Africa,−
$312 per HIA for a PMTCT intervention inMalawi, and $470perHIA for a
VMMC intervention in Uganda [18,49,62].
The median CERs for each intervention type were as follows: $2967
per HIA and $-388/DALY averted for VMMC, $13,267 per HIA and $799
per QALY gained for PrEP, $7903 per HIA and $890 per DALY averted
for TasP, $1421 per HIA and $191 per DALY averted or QALY gained
for PMTCT, $1143 per HIA and $392/DALY averted for other biomedical
interventions (microbicides, vaccination, praziquantel treatment, com-
bination prevention, condom distribution), and $3575/HIA and $345/
DALY averted for structural interventions (partner notification, cash
transfer programs). For several of the intervention types, scenarios
that prioritized specific sub-populations based on age and/or risk factors
were more cost-effective than scenarios that targeted the general pop-
ulation (Figs. 2–7).
Table 3 and Fig. 8 provide the results of the quality assessment of
each study using the CHEERS checklist.
4. Discussion
This review summarizes the evidence to date on recent studies of the
cost-effectiveness of HIV prevention interventions and serves as an SSA-
specific update to the 2009 review by Galarraga et al. [9] Results from
this review illustrate that established interventions, such as VMMC
and PMTCT, remain cost-effective, as previously found in the 2009
Records found through database searching (n = 1,258) 
Pubmed/MEDLINE, n = 863
Web of Science, n = 243
Econ-Lit, n = 91
Embase, n = 61
African Index Medicus, n = 0
Addional resources found through grey literature search and 
reference lists
(n = 45)
Records aer duplicates removed
(n = 1,115)
Records screened
(n = 1,115)
Records excluded by tle/abstract:
(n = 969)
Full-text arcles 
assessed for eligibility
(n = 146)
Full text arcles excluded (n = 86)
Relevant cost assessment not included, n = 67
Does not meet eligibility requirements, n = 15
Reviews, n = 4
Studies included
(n = 60)
Fig. 1. Flowchart diagram for study selection.
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Table 1
Study design and setting overview.
Reference Study design Setting Population Time
horizon
HIV prevalencea Perspectiveb Intervention description
VMMC
Binagwaho et al. (2010) [15] Deterministic compartmental
simulation
Rwanda 0-49 yoc, male population Lifetime 2.7% Health care payer Scale-up of VMMC to infants,
adolescents, and adults
Njeuhmeli et al. (2011) [16] Deterministic compartmental
simulation
Sub-Saharan Africa 15-49 yo, general population Lifetime 4.8% Health care payer Scale-up of VMMC
Uthman et al. (2011) [17] Probabilistic decision analysis Sub-Saharan Africa 15+ yo, male population Lifetime 5.5% Health care payer Uptake of VMMC
Duffy et al. (2013) [18] Cross-sectional descriptive
cost-analysis
Uganda 18 yo and older, male population Lifetime 5.9% Health care payer PrePex device for VMMC
Menon et al. (2014) [19] Impact analysis Tanzania 10-49 yo, male population Lifetime 4.5% Health care payer Scale-up of VMMC
Awad et al. (2015) [20] Deterministic compartmental
simulation
Zimbabwe 10-49 yo, male population 15 years 13.3% Health care payer Prioritisation of VMMC
subpopulations by age, geographic
location, sexual risk profile
Awad et al. (2015) [21] Deterministic compartmental
simulation
Zambia 10-49 yo, male population 15 yearsc 11.5% Health care payer Prioritisation of VMMC
subpopulations by age, geographic
location, sexual risk profile
Haacker et al. (2016) [22] Deterministic compartmental
simulation
South Africa 15-59, male population Lifetime 18.8% Health care payer Age prioritised VMMC scale up
Kripke et al. (2016) [23] Deterministic compartmental
simulation
Malawi 10+ yo; male population 15 years 9.6% Health care payer Age prioritised VMMC scale up
Kripke et al. (2016) [24] Deterministic compartmental
simulation
Zimbabwe 20-29 yo; male population 15 years 13.3% Health care payer Age prioritised VMMC scale up
Kripke et al. (2016) [25] Deterministic compartmental
simulation
Sub-Saharan Africa 10-49 yo; male population 15 years 4.8% Health care payer Age prioritised VMMC scale up
Kripke et al. (2016) [26] Deterministic compartmental
simulation
Eswatini 10-49 yo; male population 15 years 27.4% Health care payer Age prioritised VMMC scale up
Kripke et al. (2016) [27] Deterministic compartmental
simulation
Malawi, South Africa,
Eswatini, Tanzania,
Uganda
10-49 yo; male population 15 years 9.6% (Malawi)
18.8% (South Africa)
27.4% (Eswatini)
4.5% (Tanzania)
5.9% (Uganda)
Health care payer Age prioritised VMMC scale up
Njeuhmeli et al. (2016) [28] Deterministic compartmental
simulation
Zimbabwe Male infants 36 years 13.3% Health care payer Early infant male circumcision
PrEP
Pretorius et al. (2010) [29] Deterministic compartmental
simulation
South Africa 15-49 yo, general population 10 years 18.8% Health care payer PrEP is scaled up to recruit all
uninfected individuals
Hallett et al. (2011) [30] Microsimulation South Africa HIV serodiscordant couples Lifetime 18.8% Health care payer PrEP for uninfected partner in
serodiscordant relationships
Cremin et al. (2013) [31] Deterministic compartmental
simulation
KwaZulu-Natal, South
Africa
15-54 yo, general population 10 years 27.0% (KZNc)ref Program Combination prevention strategies
of VMMC, early ART, and PrEP
Nichols et al. (2013) [32] Deterministic compartmental
simulation
Macha, Zambia 12+ yo, general population 10 years 7.7% (Macha) Health care payer Prioritisation of PrEP
Verguet et al. (2013) [33] Deterministic compartmental
simulation
Sub-Saharan Africa 15-49 yo, general population 5 years 4.8% Health care payer PrEP intervention to pre-existing
levels of MC, ART, and condom use
Alistar et al. (2014) [34] Dynamic compartmental simulation South Africa 15-49 yo, general population 20 years 18.8% Health care payer PrEP is scaled up to recruit all
uninfected individuals
Nichols et al. (2014) [35] Deterministic compartmental
simulation
Macha, Zambia 12+ yo, general population 40 years 7.7% (Macha) Health care payer Uptake of PrEP and TasP in
combination
Cremin et al. (2015) [36] Deterministic compartmental
simulation
Nyanza province,
Kenya
General population 5 years 13.9% (Nyanza) Health care payer Dynamic interaction between key
determinants of PrEP impact and
cost-effectiveness
Cremin et al. (2015) [37] Deterministic compartmental
simulation
Gaza province,
Mozambique
Adult male mine workers 5 years 30.0% (female)
17.0% (male)
Health care payer Time-limited PrEP uptake among
sexual partners of miners
Ying et al. (2015) [38] Micro-costing analysis Uganda HIV serodiscordant couples 10 years 7.1% Program Targeted PrEP for serodiscordant
couples
Glaubius et al. (2016) [39] Deterministic compartmental
simulation
South Africa 15-54 yo, general population 1) 10yrs
2) lifetime
18.8% Societal Long-acting injective antiretrovirals
used for PrEP
Walensky et al. (2016) [40] Deterministic compartmental South Africa 18-25 yo, high risk women 5 years Incidence: 5.0% Program Long-acting PrEP
(continued on next page)
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Table 1 (continued)
Reference Study design Setting Population Time
horizon
HIV prevalencea Perspectiveb Intervention description
simulation (high risk women)
Cremin et al. (2017) [41] Deterministic compartmental
simulation
Nairobi, Kenya Key populations 10 years 4.8% Health care payer PrEP provided to FSW
TasP
Barnighausen et al. (2012) [42] Discrete time mathematical model South Africa 15+ yo, general population 10 years 18.8% Health care payer
Increased coverage of TasP, ART
under the current WHO eligibility
guidelines, and MMC
Granich et al. (2012) [43]
Deterministic compartmental
simulation
South Africa 15+ yo, general population
1) 5 years
2) 40 years
18.8% Program
Enhanced combination prevention
strategy
Smith et al. (2015) [44]
Individual-based simulation
modelling study
KwaZulu-Natal, South
Africa
18+ yo, general population 10 years 27.0% (KZN)ref Health care payer Home HIV counselling and testing
Bershteyn et al. (2016) [45]
Individual-based simulation
modelling study
South Africa General population 20 years 18.8% Health care payer
Age-targeting outreach with HIV
treatment and prevention
Ying et al. (2016) [46] Dynamic compartmental model
KwaZulu-Natal, South
Africa
General population 10 years 27.0% (KZN)ref Program Home HIV testing and counselling
PMTCT
Halperin et al. (2009) [47] Modelling analysis Sub-Saharan Africa Pregnant, HIV-infected women 1 year 4.8% Service delivery
Antiretroviral prophylaxis programs
and family planning programs
Nakakeeto et al. (2009) [48] Forecasting model
Burkina Faso,
Cameroon,
Cote d’Ivoire,
Malawi, Rwanda,
Tanzania, and Zambia
HIV-infected women, HIV-exposed
infants
8 years
0.8% (Burkina Faso)
3.7% (Cameroon)
2.8% (Cote d’Ivoire)
9.6% (Malawi)
2.7% (Rwanda)
4.5% (Tanzania)
11.5% (Zambia)
Health care payer
PMTCT package including: family
planning, HIV testing and
counselling, and provision of
antiretroviral and cotrimoxazole
prophylaxis
Orlando et al. (2010) [49] Cost-effectiveness analysis Malawi Pregnant, HIV-infected women 42 months 16.9% (ANC) Societal and Private HAART-based intervention
Robberstad et al. (2010) [50] Decision analysis Tanzania Pregnant, HIV-infected women 18 months 6.6% (ANC) Health care payer HAART-based intervention
Shah et al. (2011) [51] Decision-based analytical model Nigeria Pregnant, HIV-infected women 1 year 2.8% Health care payer
2009 WHO PMTCT guidelines
(long-course ART)
Kuznik et al. (2012) [52] Cost-effectiveness analysis Uganda Pregnant, HIV-infected women 19.3 years 7.1% Health care payer Combination ART
Binagwaho et al. (2013) [53] Cost-effectiveness analysis Rwanda
HIV-infected pregnant women and
their infants
Lifetime 2.7% Health care payer
Dual ARV and short course HAART
prophylaxis with breastfeeding or
replacement feeding
Fasawe et al. (2013) [54] Decision analysis Malawi Pregnant, HIV-infected women 10 years 16.9% (ANC) Health care payer Implementation of Option B+
Maredza et al. (2013) [55] Cost-effectiveness analysis South Africa Pregnant, HIV-infected women 24 months 28.0% (ANC) Health care payer HAART-based intervention
Gopalappa et al. (2014) [56]
Deterministic compartmental
simulation
Kenya, South Africa,
Zambia
15-49 yo, female population Lifetime
5.9% (Kenya)
18.8% (South Africa)
11.5% (Zambia)
Program Implementation of Option B+
Ishikawa et al. (2014) [57] Decision analysis Zambia Pregnant, HIV-infected women 18 months 11.5% Health care payer
Comparison between Option A,
Option B, and Option B+
Yu et al. (2014) [58] Decision analysis South Africa Pregnant, HIV-infected women 18 months 28.0% (ANC) Health care payer
1) tested and treated promptly at
any time during pregnancy
(promptly treated cohort), 2) no
testing or treatment until after
delivery and appropriate standard
treatments were offered (remedy
treated cohort)
Zulliger et al. (2014) [59] Cost-effectiveness analysis South Africa Pregnant, HIV-infected women 1 year 28.0% (ANC) Health care payer Expedited initiation onto lifelong
ART in pregnant women who met
South African ART eligibility criteria
Price et al. (2016) [60] Decision analysis Zambia Pregnant women Lifetime 11.5% Health care payer Daily oral PrEP during pregnancy
and breastfeeding
Tweya et al. (2016) [61] Individual-based simulation
modelling study
Malawi Primigravida women 50 years 16.9% (ANC) Health care payer Option B vs. Option B+
Other biomedical
Verguet et al. (2010) [62] Cost-effectiveness analysis South Africa 15-49 yo, female population 1 year 26.3% (Female) Health care payer
Impact of microbicides distributed
alongside condoms
Williams et al. (2011) [63] Dynamic compartmental model South Africa General population 20 years 18.8% Health care payer Tenofovir gel uptake by sexually
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active women
Long et al. (2013) [64] Dynamic compartmental simulation South Africa 15-49 yo, general population 10 years 18.8% Health care payer HIV screening and counselling, ART,
VMMC, microbicides
Mbah et al. (2013) [65] Dynamic compartmental simulation Zimbabwe 15-49 yo, female population 10 years 13.3% Health care payer Praziquantel as a preventive
anthelminthic chemotherapy
Terris-Prestholt et al. (2014) [66] Deterministic compartmental
simulation
Gauteng Province,
South Africa
15-49 yo, general population +
FSW and their partners
15 years 17.6% (Gauteng) Health care payer Uptake of tenofovir gel by women
Mvundura et al. (2015) [67] Impact analysis Sub-Saharan Africa 15-49 yo, general population 1 year 4.8% Health care payer Distribution of 100,000 female
condoms
Moodley et al. (2016) [68] Semi-Markov simulation South Africa Adolescents enrolled in school Lifetime 10.2% (females 15-24)
3.9% (males 15-24)
Health care payer Hypothetical HIV vaccination
provided to adolescent students
Moodley et al. (2016) [69] Semi-Markov simulation South Africa Adolescents girls enrolled in school Lifetime 10.2% (females 15-24)
3.9% (males 15-24)
Health care payer National implementation of
hypothetical HIV vaccination to
adolescents
Wall et al. (2018) [70] Cost-benefit analysis and
cost-effectiveness analysis
Zambia HIV serodiscordant couples 5 years 11.5% Donor Couples’ testing and counselling
with TasP for seropositive partner
Behavior change
Enns et al. (2011) [71] Stochastic network simulation Eswatini, Tanzania,
Uganda, Zambia
15-49 yo, general population 10 years 27.4% (Eswatini)
4.7% (Tanzania)
7.1% (Uganda)
11.5% (Zambia)
Program Concurrency reduction campaigns
focused on behaviour change
scenario: 1) increased monogamy,
2) high-risk partnership reduction,
3) untargeted partnership reduction
Structural
Fieno et al. (2014) [72] Cost simulation South Africa Women aged 15-20 yo, bottom
quarter of income distribution
6 years 18.8% Health care payer Cash transfers
Remme et al. (2014) [73] Cost-benefit analysis and
cost-effectiveness analysis
Malawi Adolescent girls attending school 18 months 9.6% Health care payer Cash transfers
Rutstein et al. (2014) [74] Decision-tree model Malawi 15-49 yo, partners of STI clinic
indexes
1 year 9.6% Health care payer Partner notification
a World Bank 2017 HIV prevalence estimates
b Health care payer perspective refers to costs incurred or saved by the governmental healthcare system; Donor perspective refers to costs incurred of saved by international donors; Program and service delivery perspective refers to costs incurred
by a stakeholders implementing HIV program; Societal perspective refers to all of society regardless of the payer; Private perspective takes into account the costs incurred by service providers
c Abbreviations: ANC= antenatal care clinic; ARV= antiretrovirals; ART = antiretroviral therapy; FSW= female sex worker; HAART= highly active antiretroviral therapy; KZN= KwaZulu-Natal, South Africa; MC=male circumcision; MMC=
medicalmale circumcision; PMTCT=prevention ofmother-to-child transmission; PrEP=pre-exposure prophylaxis; TasP= treatment as prevention;VMMC=voluntarymedicalmale circumcision;WHO=WorldHealthOrganization; yo=years old.
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Table 2
Intervention cost and output results.
Reference Scenario Outcome measure Cost-effectiveness
measure reported in
publication (US$)
Cost-effectiveness
measure (US$ 2018)
Discount
rate
Country GDP per capita
(current US$), 2018a [76]
VMMC
Binagwaho et al.
(2010) [15]
Infants 1288 HIAl Cost-saving -- 3% Rwanda: $800 ⋅21
Adolescents 1283 HIA CERl = $3,932/HIA $4,698/HIA
Adults 859 HIA CER = $4,949/HIA $5,914/HIA
Njeuhmeli et al.
(2011) [16]
80% VMMC coverage in 13
countries
9 VMMCs/1 HIA $809/HIA $927/HIA NR SSA: $1,620 ⋅00
Uthman et al.
(2011) [17]
All adult males 15 ⋅5 DALYl averted/HIA $-325/DALY averted
(cost savings)
$-388/DALY averted 3% SSA: $1,620 ⋅00
Duffy et al.
(2013) [18]
Surgical circumcision method NRm $430/HIA $470/HIA NR Uganda: $717 ⋅50
PrePex circumcision method NR $580/HIA $634/HIA
Menon et al.
(2014) [19]
Scale-up and maintenance of 80%
VMMC coverage
NR $3,200/HIA $3,668/HIA 3% Tanzania: $1,090 ⋅00
Awad et al.
(2015) [20]
Current VMMC scale-up program 326,000 HIA
11 VMMCs/1 HIA
(2010-2025)
$1,010/HIA $1,072/HIA 3% Zimbabwe: $1,270 ⋅00
VMMC program with
subpopulation prioritization
10-53 VMMCs/1 HIA $811-$5,518/HIA $861-$5,861/HIA
Awad et al.
(2015) [21]
Current VMMC scale-up program 306,000 HIA
23 VMMCs/1 HIA
(2010-2017)
12 VMMCs/1 HIA
(2017-2025)
$1,089/HIA $1,156/HIA 3% Zambia: $1,145 ⋅00
VMMC program with
subpopulation prioritization
11-36 VMMCs/1 HIA $888-$3300/HIA $943-$3505/HIA
Haacker et al.
(2016) [22]
VMMC at 0 yo 4⋅2 VMMCs/HIA $859/HIA $919/HIA 5% South Africa: $6,560 ⋅00
VMMC at 20 yo 4⋅4 VMMCs/HIA $659/HIA $705/HIA
VMMC at 55 yo 214 ⋅2 VMMCs/HIA $24,157/HIA $25,846/HIA
Kripke et al.
(2016) [23]
60% coverage among 10-29 yo 79 HIA $5,100/HIA $5,307/HIA 3% Malawi: $349 ⋅13
60% coverage among 10–34 yo 92 HIA $4,600/HIA $4,786/HIA
60% coverage among 10–49 yo 106 HIA $4,600/HIA $4,786/HIA
60% coverage among 15–49 yo 104 HIA $3,600/HIA $3,746/HIA
80% coverage among 15–49 yo 148 HIA $3,500/HIA $3,642/HIA
Kripke et al.
(2016) [24]
80% Scenario: Scale up to 80%
among 10-29 yo
87,000 HIA $4,800/HIA $4,994/HIA 3% Zimbabwe: $1,270 ⋅00
Base Scenario: Scale up to 80%
among 10-19 yo
63,000 HIA $6,000/HIA $6,243/HIA
Scenario A: 80% Scenario with 2x
unit cost for 20-29 yo
78,000 HIA $6,600/HIA $6,867/HIA
Scenario B: 80% Scenario with 2x
unit costs for 20-24 yo and 3x unit
costs for 25-29 yo
83,000 HIA $7,200/HIA $7,492/HIA
Kripke et al.
(2016) [25]
Actual VMMC performance
through 2014
240,000 HIA (229,000,
572,000)
$4,400/HIA (median
over 14 countries)
$4,578/HIA 3% (costs
only)
SSA: $1,620 ⋅00
80% coverage among 15-49 yo 1,082,000 HIA (744,000,
1,839,000)
NR --
Kripke et al.
(2016) [26]
50% EIMC coverage/80% coverage
among 10-24 yo
20,000 HIA (14,000,
24,000)
$1,500/HIA ($1,100,
$1,900)
$1,560/HIA ($1,144,
$1,977)
3% Eswatini: $4,090 ⋅00
50% EIMC coverage/80% coverage
among 10-29 yo
27,000 HIA (19,000,
34,000)
$1,300/HIA ($900,
$1,600)
$1,352/HIA ($936,
$1,664)
50% EIMC coverage/80% coverage
among 10-34 yo
29,000 HIA (21,000,
38,000)
$1,200/HIA ($900,
$1,600)
$1,248/HIA ($936,
$1,664)
Kripke et al.
(2016) [27]
80% coverage among 10-49 yo Malawi: 149,000 HIA $4,600/HIA $4,600/HIA Malawi: $349 ⋅13
South Africa: $6,560 ⋅00
Eswatini: $4,090 ⋅00
Tanzania: $1,090 ⋅00
Uganda: $717 ⋅50
South Africa: 375,000 HIA $2,700/HIA $2,700/HIA
Eswatini: 31,500 HIA $1,200/HIA $1,200/HIA
Tanzania: 53,400 HIA $5,800/HIA $5,800/HIA
Uganda: 486,000 HIA $1,500/HIA $1,500/HIA
80% coverage among 15-49 yo Malawi: 148,000 HIA $3,500/HIA $3,500/HIA
South Africa: 372,000 HIA $2,200/HIA $2,200/HIA
Eswatini: 32,200 HIA $900/HIA $900/HIA
Tanzania: 50,500 HIA $4,100/HIA $4,266/HIA
Uganda: 475,000 HIA $1,100/HIA $1,144/HIA
80% coverage among 15-24 yo Malawi: 82,000 HIA $4,300/HIA $4,474/HIA
South Africa: 182,000 HIA $2,500/HIA $2,601/HIA
Eswatini: 18,900 HIA $1,000/HIA $1,040/HIA
Tanzania: 28,300 HIA $4,900/HIA $5,098/HIA
Uganda: 241,000 HIA $1,400/HIA $1,456/HIA
80% coverage among 15-29 yo Malawi: 109,000 HIA $3,700/HIA $3,850/HIA
South Africa: 246,000 HIA $2,200/HIA $2,289/HIA
Eswatini: 25,700 HIA $900/HIA $936/HIA
Tanzania: 36,200 HIA $4,300/HIA $4,474/HIA
Uganda: 324,000 HIA $1,200/HIA $1,248/HIA
80% coverage among 15-34 yo Malawi: 128,000 HIA $3,500/HIA $3,642/HIA
South Africa: 303,000 HIA $2,100/HIA $2,185/HIA
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Reference Scenario Outcome measure Cost-effectiveness
measure reported in
publication (US$)
Cost-effectiveness
measure (US$ 2018)
Discount
rate
Country GDP per capita
(current US$), 2018a [76]
Eswatini: 29,700 HIA $900/HIA $936/HIA
Tanzania: 43,200 HIA $4,000/HIA $4,162/HIA
Uganda: 388,000 HIA $1,100/HIA $1,144/HIA
80% coverage among 10-24 yo Malawi: 83,000 HIA $6,100/HIA $6,347/HIA
South Africa: 190,000 HIA $3,600/HIA $3,746/HIA
Eswatini: 19,600 HIA $1,400/HIA $1,456/HIA
Tanzania: 31,300 HIA $7,800/HIA $8,116/HIA
Uganda: 256,000 HIA $2,100/HIA $2,185/HIA
80% coverage among 10-29 yo Malawi: 110,000 HIA $5,100/HIA $5,307/HIA
South Africa: 250,000 HIA $3,000/HIA $3,121/HIA
Eswatini: 26,300 HIA $1,200/HIA $1,248/HIA
Tanzania: 38,700 HIA $6,800/HIA $7,076/HIA
Uganda: 337,000 HIA $1,700/HIA $1,769/HIA
Njeuhmeli et al.
(2016) [28]
Scale up of VMMC among
adolescents
266,000 HIA $4,127/HIA $4,415/HIA 3% Zimbabwe: $1,270 ⋅00
Introduction of EIMC into existing
VMMC program
268,000 HIA $5,256/HIA $5,623/HIA
PrEP
Pretorius et al.
(2010) [29]
Targeted PrEP for 25-35 yo
women
NR $12,500 - $20,000/HIA $14,328 - $22,924/HIA NR South Africa: $6,560 ⋅00
Hallett et al.
(2011) [30]
PrEP always used after HIV
diagnosis in serodiscordant
couple
15% - 52% HIA $0 - $26,000/HIA $0 - $28,944/HIA 3% South Africa: $6,560 ⋅00
PrEP used up through ART
initiation for HIV infected partner
11% - 36% HIA $-2,200 - $21,000/HIA $-2,449 - $26,025/HIA
PrEP used only during periods of
trying to conceive a pregnancy
and during pregnancy
1% - 2% HIA $-6,000 - $8,000/HIA $-6,679 - $8,906/HIA
Cremin et al.
(2013) [31]
PrEP provided to 7.3% of
uninfected 15-24 yo
3⋅2% HIA $10,540/HIA $11,362/HIA 3% South Africa: $6,560 ⋅00
PrEP provided to 4.4% of
uninfected 15-54 yo
3⋅6% HIA $9,390/HIA $10,122/HIA
Nichols et al.
(2013) [32]
Non-prioritized PrEP 2,333 HIA;
23,571 QALYsl gained
$1,843/QALY gained $2,051/QALY gained 3% Zambia: $1,145 ⋅00
Prioritized PrEP 3,200 HIA;
36,216 QALYs gained
$323/QALY gained $359/QALY gained
Verguet et al.
(2013) [33]
PrEP intervention 200 - 94,100 HIA
3,300 - 1,266,000 DALYs
averted
$550 - $44,600/DALY
averted
$612 - $49,651/DALY
averted
NR SSA: $1,620 ⋅00
Alistar et al.
(2014) [34]
10% Guidelines ART, 50% Focused
PrEP
1,837,744 HIA CER = cost saving CER = cost saving 3% South Africa: $6,560 ⋅00
10% Guidelines ART, 100% Focused
PrEP
3,084,508 HIA CER = cost saving CER = cost saving
50% Guidelines ART, 100% General
PrEP
3,642,543 HIA $163/QALY gained $174/QALY gained
100% Guidelines ART, 100%
Focused PrEP
3,840,111 HIA $229/QALY gained $245/QALY gained
50% Universal ART, 100% Focused
PrEP
4,468,827 HIA $276/QALY gained $295/QALY gained
100% Universal ART, 100% Focused
PrEP
4,663,411 HIA $302/QALY gained $323/QALY gained
10% Guidelines ART, 50% General
PrEP
2,998,344 HIA $1,172/QALY gained $1,253/QALY gained
10% Guidelines ART, 100% General
PrEP
3,381,214 HIA $1,158/QALY gained $1,239/QALY gained
Nichols et al.
(2014) [35]
Treatment available at CD4 b500
cells/μL
3388 HIA;
40,643 QALYs gained
CER = $62/QALY
gained ($46–$75)
ICER = $62/QALY
gained ($46–$75)
CER= $69/QALY gained
($51–$83)
ICER = $69/QALY
gained ($51–$83)
3% Zambia: $1,145 ⋅00
Prioritized PrEP (most sexually
active)
1502 HIA;
13,611 QALYs gained
CER = $4,103/QALY
gained
($2,890–$5,803)
ICERl = dominated
CER = $4,567/QALY
gained ($3,217 –
$6,460)
ICER = dominated
Prioritized PrEP (mostly sexually
active and treatment available at
CD4 b500 cells/μL)
4494 HIA;
50,936 QALYs gained
CER = $1,153/QALY
gained ($686–$1,756)
ICER = dominated
CER = $1,283/QALY
gained ($763–$1,954)
ICER = dominated
Non-prioritized PrEP (randomly
distributed)
4053 HIA;
40,318 QALYs gained
CER = $3,730/QALY
gained
($2,454–$5,691)
ICER = dominated
CER = $4,152/QALY
gained ($2,731–$6,335)
ICER = dominated
Non-prioritized PrEP (randomly
distributed and treatment
available at CD4 b500 cells/μL)
5894 HIA;
67,835 QALYs gained
CER = $2,253/QALY
gained
($1,672–$3,188)
CER = $2,508/QALY
gained ($1,861–$3,549)
ICER = dominated
(continued on next page)
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Reference Scenario Outcome measure Cost-effectiveness
measure reported in
publication (US$)
Cost-effectiveness
measure (US$ 2018)
Discount
rate
Country GDP per capita
(current US$), 2018a [76]
ICER = dominated
Cremin et al.
(2015) [36]
Standard PrEP intervention ($20
million budget)
24,603 (~11%) HIA
(3,750 - 49,450)
$2,060 - $36,360/HIA $2,293 - $40,478/HIA 3% South Africa: $6,560 ⋅00
Cremin et al.
(2015) [37]
All uninfected women eligible to
receive PrEP
NR $15,647/HIA $17,419/HIA 3% Mozambique: $481 ⋅25
Providing PrEP only to partners of
miners
NR $71,374/HIA $79,458/HIA
Providing PrEP only to partners of
miners and only during the last six
weeks of the year
NR $9,538/HIA $10,618/HIA
Ying et al. (2015)
[38]
40% overall ART coverageb; 10%
coverage for persons with CD4
350-500 cells/μL
94,000 HIA Ref. -- 3% Uganda: $717 ⋅50
Increase ART Coverage (50%
coverage for persons with CD4
350-500 cells/μL)
104,000 HIA Dominated --
Targeted PrEP and ART to 90%
serodiscordant couples
120,000 HIA $1,340/HIA $1,466/HIA
Glaubius et al.
(2016) [39]
Optimistic scenario,
Non-prioritized PrEP
1⋅6% - 9⋅1% HIA $20,905 - $22,022/HIA
$176,755 -
$181,734/LYG
$22,874 - $24,096/HIA
$192,313 -
$198,856/LYG
3% South Africa: $6,560 ⋅00
Optimistic scenario,
Age-prioritized PrEP
2⋅9% - 17 ⋅2% HIA $10,880 - $11,094/HIA
$84,418 - $85,105/LYG
$11,905 - $12,139/HIA
$92,371 - $93,123/LYG
Optimistic scenario,
Risk-prioritized PrEP
8⋅1% HIA $11,094/HIA
$85,105/LYG
$12,139/HIA
$93,123/LYG
Conservative scenario,
Non-prioritized PrEP
1⋅0 - 5⋅5% HIA $35,090 - $37,137/HIA
$276,605 -
$284,781/LYG
$38,396 - $40,635/HIA
$302,665 -
$311,611/LYG
Conservative scenario,
Age-prioritized PrEP
1⋅8 - 10 ⋅3% HIA $18,429 - $19,213/HIA
$133,428 -
$135,695/LYG
$20,165 - $21,023/HIA
$145,999 -
$148,479/LYG
Conservative scenario,
Risk-prioritized PrEP
4⋅4% HIA $1,242/HIA
$11,568/LYG
$1,359/HIA
$12,657/LYG
Walensky et al.
(2016) [40]
Standard PrEP 127 HIA $10,100/HIA
Cost saving (vs. no
PrEP)
$10,806/HIA 3% South Africa: $6,560 ⋅00
Long-acting PrEP 156 HIA $12,400/HIA
Cost saving (vs. no
PrEP)
$13,267/HIA
Cremin et al.
(2017) [41]
50% PrEP coverage to all FSW NR $65,160/HIA (95% CI:
$43,520 - $95,250)
$66,404/HIA (95% CI:
$44,351 - $97,069)
0% Kenya: $1,870 ⋅00
50% PrEP coverage to high-risk
FSW
NR $10,920/HIA (95% CI:
$4,700 - $51,560)
$11,128/HIA (95% CI:
$4,789 - $52,544)
TasP
Barnighausen
et al. (2012)
[42]
Coverage: 70% ART, 20% TasP, 45%
MMCl
650,000 HIA (compared to
50% ART and 45% MMC)
$7,157/HIA $7,813/HIA 3% South Africa: $6,560 ⋅00
Coverage: 80% ART, 40% TasP, 45%
MMC
1,000,000 HIA $7,482/HIA $8,186/HIA
Coverage: 80% ART, 60% TasP, 45%
MMC
1,100,000 HIA $7,937/HIA $8,684/HIA
Coverage: 80% ART, 80% TasP, 45%
MMC
1,260,000 HIA $8,370/HIA $9,158/HIA
Granich et al.
(2012) [43]
ART initiation at CD4 count ≤350
cells/μL vs. ≤200 cells/μL
200,000-1,400,000 HIA NR -- 3% South Africa: $6,560 ⋅00
ART initiation at CD4 count b500
cells/mm3 vs. ≤350 cells/μL
200,000-1,500,000 HIA $182/DALY averted $199/DALY averted
ART initiation at all CD4 levels vs.
CD4 count ≤500 cells/μL
300,000-1,400,000 HIA $1,381/DALY averted $1,510/DALY averted
Smith et al.
(2015) [44]
High ART cost|Low ART cost 3% South Africa: $6,560 ⋅00
ART initiation at ≤200 cells/μL (vs.
status quo)
2,000 DALYs averted $22,300/HIA |
$12,900/HIA
$1,230/DALY averted |
$414/DALY averted
$24,400/HIA |
$14,115/HIA
$1,345/DALY averted |
$453/DALY averted
ART initiation at ≤350 cells/μL 3,100 DALYs averted $10,400/HIA |
$4,210/HIA
$1,020/DALY averted |
$788/DALY averted
$11,379/HIA |
$4,606/HIA
$1,116/DALY averted |
$851/DALY averted
ART initiation at b500 cells/μL 3,300 DALYs averted $8,910/HIA |
$2,780/HIA
$1,090/DALY averted |
$342/DALY averted
$9,749/HIA | $3,041/HIA
$1,192/DALY averted |
$374/DALY averted
Universal ART 3,300 DALYs averted $8,190/HIA |
$1,960/HIA
$1,300/DALY averted |
$8,961/HIA | $2,144/HIA
$1,422/DALY averted |
$339/DALY averted
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measure reported in
publication (US$)
Cost-effectiveness
measure (US$ 2018)
Discount
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Country GDP per capita
(current US$), 2018a [76]
$310/DALY averted
Bershteyn et al.
(2016) [45]
Targeting 10-30 yo NR $6,238/HIA $6,491/HIA 3% South Africa: $6,560 ⋅00
Targeting 20-30 yo NR $5,031/HIA $5,235/HIA
Targeting 22-27 yo NR $4,279/HIA $4,452/HIA
Targeting 25-27 yo NR $3,967/HIA $4,128/HIA
Targeting to full population NR $10,812/HIA $11,250/HIA
Ying et al. (2016)
[46]
Base case (36% of HIV-infected
people achieving viral
suppression)
Ref. Ref. -- 3% South Africa: $6,560 ⋅00
Home HTC (48% of HIV-infected
people achieving viral
suppression)
152,000 HIA $3,290/HIA $3,546/HIA
Home HTC+High Viral Load (60%
ART uptake if CD4N350 cells/μL
and VLN10,000 copies/mL)
183,000 HIA $3,320/HIA $3,579/HIA
Home HTC + CD4 (60% ART
uptake if CD4 350–500 cells/μL)
195,000 HIA $2,960/HIA $3,190/HIA
PMTCT
Halperin et al.
(2009) [47]
Perinatal HIV transmission
prevention program
241,596 HIA $543/HIA $631/HIA by perinatal
infection
NR SSA: $1,620 ⋅00
Services to prevent unintended
pregnancies
72,000 HIA $359/HIA $417/HIA by
unintended pregnancy
Nakakeeto et al.
(2009) [48]
Meeting UNGASSl targets for
PMTCT by 2010
NR Burkina Faso:
$2,292/HIA
$2,741/HIA 3% Burkina Faso: $734.03
Cameroon: $1,540 ⋅00
Cote d’Ivoire: $1,790 ⋅00
Malawi: $349 ⋅13
Rwanda: $800 ⋅21
Tanzania: $1,090 ⋅00
Zambia: $1,145 ⋅00
Cameroon: $1,366/HIA $1,633/HIA
Cote d’Ivoire:
$1,391/HIA
$1,663/HIA
Malawi: $965/HIA $1,154/HIA
Rwanda: $1,085/HIA $1,297/HIA
Tanzania: $1,068/HIA $1,277/HIA
Zambia: $829/HIA $991/HIA
Orlando et al.
(2010) [49]
PMTCT programwith VCT, HAART,
treatment of malnutrition, TB,
malaria, STDs (private
perspective)
370 HIA
10,449 DALYs averted
$998/HIA
$35 ⋅36/DALY averted
$1,193/HIA
$42 ⋅30/DALY averted
3% Malawi: $349 ⋅13
PMTCT programwith VCT, HAART,
treatment of malnutrition, TB,
malaria, STDs (public perspective)
370 HIA
10,449 DALYs averted
$-261/HIA
$-16 ⋅55/DALY averted
$-312/HIA
$-19 ⋅80/DALY averted
Robberstad et al.
(2010) [50]
Single-dose NVPl 0⋅00051 HIA (per
pregnancy)
0⋅0129 DALYs averted
$26,826/HIA
$1,071/DALY averted
$20,749/HIA
$1,227/DALY averted
NR Tanzania: $1,090 ⋅00
PMTCT Plusc 0⋅00267 HIA (per
pregnancy)
0⋅067 DALYs averted
$7,204/HIA
$287/DALY averted
$8,257/HIA
$328/DALY averted
Shah et al.
(2011) [51]
Current PMTCT Coverage (10% of
all HIV-infected women)
1400 HIA $3,620/HIA $4,149/HIA 3% Nigeria: $2,050 ⋅00
Current ANC Coverage (58% of
HIV-infected women)
7680 HIA $3,203/HIA $3,671/HIA
Full PMTCT Coverage (100% of
HIV-infected women)
14400 HIA $3,167/HIA $3,630/HIA
Kuznik et al.
(2012) [52]
18 months ART vs. sdNVPl 5⋅21 DALYs averted $46/DALY averted $51/DALY averted 3% Uganda: $717 ⋅50
18 months ART vs. DTl 3⋅22 DALYs averted $99/DALY averted $110/DALY averted
18 months ART vs. no treatment 8⋅58 DALYs averted $34/DALY averted $37/DALY averted
Lifetime ART vs. sdNVP 19 ⋅2 DALYs averted $205/DALY averted $228/DALY averted
Lifetime ART vs. DT 11 ⋅87 DALYs averted $354/DALY averted $394/DALY averted
Lifetime ART vs. no treatment 31 ⋅6 DALYs averted $172/DALY averted $191/DALY averted
Binagwaho et al.
(2013) [53]
Dual ARV + breastfeeding NR Dominated -- 3% Rwanda: $800 ⋅21
Dual ARV + replacement feeding NR Dominated --
Sc-HAART + 6 mo. breastfeeding NR Dominated --
Sc-HAART + 12 mo. breastfeeding 9,837 HIV uninfected
children still alive
-- --
Sc-HAART + 18 mo. breastfeeding 9,292 HIV uninfected
children still alive
ICER = $11,882/HIA
(compared to 12 mo.)
$12,882/HIA
Sc-HAART + replacement feeding NR Dominated --
Fasawe et al.
(2013) [54]
Current Practice 4,503 HIA $816/HIA
$37/QALY gained
$935/HIA
$42/QALY gained
3% Malawi: $349 ⋅13
Option A 15,606 HIA $844/HIA
$37/QALY gained
$967/HIA
$42/QALY gained
Option B 15,997 HIA $1,331/HIA
$60/QALY gained
$1,525/HIA
$68/QALY gained
Option B+ 15,997 HIA $1,265/HIA
$57/QALY gained
$1,450/HIA
$65/QALY gained
Maredza et al. Increase coverage of extended 220 DALYs averted Dominant Dominant 3% South Africa: $6,560 ⋅00
(continued on next page)
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Cost-effectiveness
measure (US$ 2018)
Discount
rate
Country GDP per capita
(current US$), 2018a [76]
(2013) [55] NVP to infants (rural)
Promote formula feeding (rural) 420 DALYs averted $1,300/DALY averted $1,490/DALY averted
Promote breastfeeding
(rural)
160 DALYs averted Dominant
--
Increase coverage of
extended NVP to infants
(urban)
90 DALYs averted Dominant
--
Promote formula
feeding
(urban)
160 DALYs averted Dominant --
Promote
breastfeeding
(urban)
-240 DALYs avertedd $3,200/DALY averted $3,667/DALY averted
Gopalappa et al.
(2014) [56]
Option B+ vs. Option A NRe Kenya: $6,015/ HIA
South Africa:
$22,987/HIA
Zambia: $6,778/HIA
Kenya: $6,763/HIA
South Africa:
$25,590/HIA
Zambia: $7,545/HIA
3% Kenya: $1,870 ⋅00
South Africa: $6,560 ⋅00
Zambia: $1,145 ⋅00
Ishikawa et al.
(2014) [57]
Option B 7,176 HIA $1,023/HIA $1,094/HIA 3% Zambia: $1,145 ⋅00
Option B+ 7,318 HIA $1,254/HIA $1,341/HIA
Yu et al. (2014)
[58]
Remedy cohortf 110 infant HIA Extended dominatedg -- 3% South Africa: $6,560 ⋅00
Remedy cohort, breastfeed 421 infant HIA Extended dominated --
Remedy cohort, replacement feed 11 infant HIA Extended dominated --
Promptly treated cohorth 698 infant HIA Undominatedi --
Promptly treated cohort,
breastfeed
360 infant HIA Extended dominated --
Promptly treated cohort,
replacement feed
883 infant HIA Undominated --
Zulliger et al.
(2014) [59]
Rapid initiation of ART in
Pregnancy pilot program
16.88 QALYs saved $1,160/QALY gained $1,291/QALY gained 3% South Africa: $6,560 ⋅00
Price et al.
(2016) [60]
Oral PrEP at first ANC visit with
HIV- test and end with
breastfeeding cessation
381 HIA $965/DALY averted $1,025/DALY averted 3% Zambia: $1,145 ⋅00
Tweya et al.
(2016) [61]
Option B+ vs. Option B 133 DALYs averted $841/DALY averted $875/DALY averted 3% Malawi: $349 ⋅13
Other biomedical
Verguet et al.
(2010) [62]
Access to condoms and
microbicide effective at 55%
1,908 HIA $-6,712/HIA $-8,356/HIA NR South Africa: $6,560 ⋅00
Williams et al.
(2011) [63]
Tenofovir 25% Coverage 250,000 HIA (20,000 –
380,000)
$2,392/HIA
($562-$4,222)
$2,662/HIA
($625-$4,700)
3% South Africa: $6,560 ⋅00
Tenofovir 90% Coverage 1,100,000 HIA (60,000 –
2,040,000)
$1,701/HIA
($420-$2,982)
$1,893/HIA
($467-$3,319)
Long et al.
(2013) [64]
Scale-up of VMMC to 75% of all
men
12 ⋅1% HIA Cost-saving -- NR South Africa: $6,560 ⋅00
Tenofovir gel used by 50% of
women
14 ⋅1% HIA $526/QALY gained $602/QALY gained
Use of PrEP by 50% of all
uninfected persons
28 ⋅4% HIA $9,009/QALY gained $10,326/QALY gained
VMMC, microbicide, and PrEP 43 ⋅5% HIA $5,739/QALY gained $6,578/QALY gained
Mbah et al.
(2013) [65]
Praziquantel treatment received
during childhood
21,120 HIA $259/HIA $314/HIA 3% Zimbabwe: $1,270 ⋅00
Praziquantel treatment received
during childhood and FGSl
prevalence is reduced relative to
those who did not receive
treatment
41,500 HIA $132/HIA $174/HIA
Terris-Prestholt
et al. (2014)
[66]
72% microbicide gel use
consistency and 54% HIV efficacy
55,366 HIA $297/DALY averted $392/DALY averted 3% South Africa: $6,560 ⋅00
Mvundura et al.
(2015) [67]
Distribution of 100,000 female
condoms
273 HIA Lower Bound: Cost
Savingsj
Higher Bound:
$154/DALY avertedk
--
Higher Bound:
$168/DALY averted
NR SSA: $1,620 ⋅00
Moodley et al.
(2016) [68]
HIV vaccine intervention for
school-based adolescents
4⋅36 QALYs gained in
lifetime
$43/QALY gained $47/QALY gained 3% South Africa: $6,560 ⋅00
Moodley et al.
(2016) [69]
60% coverage at $12 per vaccine
dose
NR $4 ⋅98/LYG (95%: $2 ⋅
77–$11 ⋅61)
$5 ⋅45/LYG (95%:
$3 ⋅03–$12 ⋅70)
3% South Africa: $6,560 ⋅00
Wall et al. (2018)
[70]
Nationwide CVCT 166,153 HIA $394/HIA $394/HIA 0% Zambia: $1,145 ⋅00
TasP for serodiscordant couples
identified by CVCT
9,656 HIA $7,930/HIA $7,930/HIA
Population TasP for all HIV+
cohabitating men and women
identified by individual HTC
17,872 HIA $12,891/HIA $12,891/HIA
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review. For newer prevention strategies, such as PrEP and TasP, many of
the studies relied on various assumptions and scenarios thatmay not re-
flect reality.
The review found that PMTCT and VMMC interventions were the
most cost-effective. Studies on PMTCT interventions, including HAART,
infant feeding methods, expedited ART, and Option B+ suggest that
these strategies are very cost-effective [47,49,50,54,56,57,59]. These
studies provide evidence supporting WHO guidelines of transitioning
from Option A and of recommending PMTCT Option B and Option B+.
When WHO began the policy transition from Option B to Option B+
in 2013, the agency conducted a preliminary cost analysis to estimate
the incremental cost of switching to the newpolicy [75]. The authors ar-
gued that researchers should develop additional cost-effectiveness
models to appropriately evaluate the cost of the policy with program-
matic data. A number of studies have since provided evidence
supporting the policy decisions around Option B+ [56,57]. However,
stakeholders should be mindful that implementation of strategies like
Option B+ raises concerns since many of these studies do not take
into account initial costs and upfront investment required to scale up
PMTCT programs to a level that can be considered cost-effective over
an extended time period [61,75]. Additionally, while the majority of
PMTCT studies included in this review focused on Prong III, only one
study addressed PMTCT Prong II by studying the expansion of family
planning services as a cost-effective method to avert HIV infections
through the prevention of unintended pregnancies [47]. This focus
may reflect recent programmatic shifts towards PMTCT Prong III and
treatment of HIV infectedwomen, even though family planning is effec-
tive in reducing MTCT.
The VMMC studies included in this review agreed that the interven-
tion was cost-effective. Seven different studies developed models that
estimated cost effectiveness of VMMC at 80% coverage, which is a com-
mon target formanyHIV prevention programs; however, achieving this
level of coverage is often not feasible in many settings [16,19,23–27].
Additional studies exploring cost effectiveness at various levels of
VMMC coverage may help inform decision makers in areas where 80%
coverage would be difficult to attain. Multiple studies explored scenar-
ios targeting VMMCat different age groups, with a consensus that prior-
itizing younger males is more favourable and cost-saving compared to
targeting the general male adult population [15,22,24].
Similarly, a common conclusion was that PrEP strategies targeting
specific risk groups were more cost-effective than general PrEP strate-
gies [29,32,34,35,39]. Four studies found that PrEP was most cost-
effective when using a prioritization strategy aimed at young individ-
uals who are most at-risk, including having more than four partners
and reporting low condom use [32,34,39,41]. The majority of included
PrEP studies were set in South Africa, a country that could perhaps bet-
ter absorb the higher costs of PrEP implementation compared with
others in the region. However, three studies in Zambia and
Mozambique agreed that prioritizing high-risk individuals would create
the most effective scenario for PrEP implementation, adding to the evi-
dence that a targeted PrEP strategy could be feasible across country set-
tings [32,35,36].
The assumption of 100% PrEP coverage considered in many studies
may be difficult to implement [11,14]. This scenario implies that every
eligible individualwould receive PrEP, whichmay not be realistic in set-
tings where universal treatment has not even been realized. Many
Table 2 (continued)
Reference Scenario Outcome measure Cost-effectiveness
measure reported in
publication (US$)
Cost-effectiveness
measure (US$ 2018)
Discount
rate
Country GDP per capita
(current US$), 2018a [76]
Behaviour change
Enns et al.
(2011) [71]
Increased monogamy 77 (8 ⋅7%) HIA NR -- 3% Eswatini: $4,090 ⋅00
Tanzania: $1,090 ⋅00
Uganda: $717 ⋅50
Zambia: $1,145 ⋅00
High-risk partnership reduction 115 (11 ⋅7%) HIA NR --
Untargeted partnership reduction 76 (8 ⋅9%) HIA NR --
Structural
Fieno et al.
(2014) [72]
Cash transfer at $5 monthly
benefit
3,400 HIA $1,650/HIA $1,919/HIA NR South Africa: $6,560 ⋅00
Cash transfer at $10 monthly
benefit
4,250 HIA $2,640/HIA $3,071/HIA
Cash transfer at $20 monthly
benefit
5,100 HIA $4,400/HIA $5,118/HIA
Remme et al.
(2014) [73]
Long-term benefits of 18-month
cash transfer trial
93,600 HIV DALYs averted $297/HIV DALY averted $345/HIV DALY averted NR Malawi: $349 ⋅13
Rutstein et al.
(2014) [74]
Passive Referral Ref. Ref. -- NR Malawi: $349 ⋅13
Provider Notification 27 ⋅5 HIA ICER = $3,560/HIA $4,080/HIA
Contract Notification 0⋅4 HIA ICER = $51,421/HIA $58,941/HIA
a Country GDP estimates retrieved from International Monetary Fund, World Economic Outlook.
b ART coverage means HIV treatment for people with CD4 b350 cells/μL and TasP coverage means HIV treatment for people with CD4 ≥ 350 cells/μL.
c PMTCT Plus refers to a HAART intervention for all HIV infected women during pregnancy and lactation, regardless of CD4 count, according to 2009 WHO guidelines.
d Negative value indicates an intervention was less effective than base case.
e Not reported for infant only infections averted.
f Women in remedy cohort received HIV testing and standard treatment only after delivery.
g Extended dominated excludes any intervention that has a higher ICER than more effective interventions.
h Women in the promptly treated cohort received HIV testing and treatment at some point during pregnancy.
i Undominated refers to strategies that are more cost-effective.
j The intervention was cost-saving in the following countries: Botswana, South Africa, Eswatini, Zambia, Zimbabwe.
k Cost($)/DALY averted for other included countries: Cameroon (43), Kenya (110), Lesotho (9), Malawi (114), Mozambique (154), Namibia (9), Tanzania (73), Uganda (25).
l Abbreviations: DT=dual therapy (zidovudine and lamivudine); ANC=antenatal care clinic; ARV=antiretrovirals; ART= antiretroviral therapy; CI= confidence intervals; DALY=
disability-adjusted life year; EIMC= early infant male circumcision; FGS= female genital schistosomiasis; FSW= female sexworker; HAART=highly-active antiretroviral therapy; HIA
=HIV infections averted; LYG= life years gained; NVP=nevirapine; PMTCT=prevention ofmother-to-child transmission; PrEP=pre-exposure prophylaxis; QALY=quality-adjusted
life year; Sc-HAART= short-course highly-active antiretroviral therapy; sdNVP= single dose nevirapine; SSA= sub-Saharan Africa; STD= sexually transmitted disease; TB= tubercu-
losis; UNGASS = UN General Assembly Special Session on AIDS; VCT = voluntary counselling and testing; VMMC= voluntary medical male circumcision; yo = years old.
m Abbreviations: NR=not reported; in certain instances, studiesmay have 1) reported cost-effectivenessmeasurewithout stating an effectivenessmeasure or 2) presented visualized
cost-effectiveness results without stating the numeric value of the cost-effectiveness measure. These instances would lead to an ‘NR’.
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studies point out that achieving such a high level of PrEP coverage
would be less cost-effective than simply increasing ART coverage. Ac-
cordingly, WHO issued recommendations in 2015 to provide PrEP as a
prevention option to individuals at substantial risk of acquiring HIV in
settings with high HIV incidence [76]. Although studies have shown
that PrEP can be cost-effective when targeted towards high-risk groups
and when assuming high adherence, it remains a challenging interven-
tion due to high costs, ethical issues, and inequitable distribution [8].
The five studies included in this review were not in agreement with
regard to the cost-effectiveness or the feasibility of TasP strategy; one
Fig. 2. Cost-effectiveness measures of VMMC interventions. Data points reflect the measures from VMMC studies reporting cost per HIV infection averted (above) and cost per DALY
averted (below). Points represent study-specific cost-effectiveness estimates; error bars represent estimate ranges, if provided in study results.
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study concluded that TasP was less cost-effective than a combination of
VMMC and ART, which is already the standard practice in many sub-
Saharan African settings [42]. From this review, it is unclear whether
or not TasP would bemore cost-effective in certain settings over others.
Despite this uncertainty, many countries have already developed and
implemented guidelines for TasP and universal test-and-treat (UTT)
Fig. 3. Cost-effectivenessmeasures of PrEP interventions. Data points reflect themeasures fromPrEP studies reporting cost per HIV infection averted (above) and cost per DALY averted or
QALY gained (below). Points represent study-specific cost-effectiveness estimates; error bars represent estimate ranges, if provided in study results.
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[77]. Healthcare investment to provide UTT services successfully is sub-
stantial, especially in extensive resource-constrained settings [78].
This review also included studies that explored cost-effectiveness of
methods that are still in development and not currently available on the
market, including long-acting PrEP injections, HIV vaccines, and
microbicide gels. The findings from these studies suggest that these in-
terventions would be cost-effective once accessible [62–64,66,68,69].
Only one study included in this review considered the reduction of
HIV incidence by estimating the intervention effect of schistosomiasis
treatment. Mbah et al. showed that mass praziquantel administration
Fig. 4. Cost-effectiveness measures of TasP interventions. Data points reflect the measures from TasP studies reporting cost per HIV infection averted (above) and cost per DALY averted
(below). Points represent study-specific cost-effectiveness estimates; error bars represent estimate ranges, if provided in study results.
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would be a cost-effective approach to reduce HIV transmission. In addi-
tion to its affordability, praziquantel treatment is very safe, well toler-
ated, and easily administered, but it has not been explicitly considered
as a HIV prevention intervention, as the link between HIV acquisition
and schistosomiasis remains unclear [65].
The vast majority of the included studies determined cost-
effectiveness based on theWHO-CHOICE guidance that considers inter-
ventions to cost-effective if the cost per DALY averted is between one
and three times the study country's GDP per capita [79]. This threshold
is becoming increasingly contested, asmany experts believe that it does
not consider governments' ability to generate the appropriate resources
or willingness to pay [80,81]. Some studies have translated HIA to
DALYs; we did not find a standard conversion that would be applicable
to the various country settings [17]. Moreover, the usefulness of this
type of threshold is especially important when discussing high cost in-
terventions, such as PrEP and TasP. Although these prevention
strategies may be considered cost-effective under certain assumptions,
this may not always translate into feasible implementation. The GDP-
based threshold is unrelated to national and donor HIV budgets, both
of which are needed to understand an intervention's affordability.
Thus, more information is need on whether many SSA countries
would be able to implement a large-scale PrEP program, although its
use as amain prevention strategy has been heavily emphasized inpolicy
discussion [8]. Many countries are already struggling to provide univer-
sal ART, and adding a high-cost strategy may apply further pressure on
resource limited prevention programs.
In the 2009 review, Galarraga et al. concluded that not enough infor-
mation regarding cost-effectiveness of many prevention strategies
existed for decision-making or policy change [9]. Their review included
many cost-effectiveness studies on interventions for behaviour change,
intravenous drug use (IDU) harm reduction, and information, educa-
tion, and communication. The present review found only two studies
Fig. 5. Cost-effectiveness measures of PMTCT interventions. Data points reflect the measures from PMTCT studies reporting cost per HIV infection averted (above) and cost per DALY
averted or QALY gained (below). Points represent study-specific cost-effectiveness estimates.
Fig. 6. Cost-effectiveness measures of biomedical interventions. Data points reflect the measures frommiscellaneous biomedical studies reporting cost per HIV infection averted (above)
and cost per DALY averted or QALY gained (below). Points represent study-specific cost-effectiveness estimates; error bars represent estimate ranges, if provided in study results.
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on behaviour change and structural interventions, with most recently
published studies focusing onbiomedical interventions. This shift repre-
sents a reflection of changing priorities of the international donor com-
munity and emerging technology available from pharmaceutical
companies. The authorsmentioned the lack of cost-effectiveness studies
on vulnerable groups, such as men who have sex with men (MSM) and
female sexworkers (FSW). Similarly, the current review found only one
study focusing on FSWs, although there are published studies on these
populations in settings outside of Africa [66,82]. The continuing dearth
of studies on these vulnerable populations in sub-Saharan Africa ought
to be addressed by future research, as costing studies can inform
policymaking.
Several limitations were recognized while conducting this review.
First, behavioral and structural interventions, like partner concurrency
reduction and condom use, have historically been included in HIV pre-
vention programs [71]. Although the studies in this paper suggest that
these strategies are cost-effective, most analyses do not separate the
effect of behaviour change on HIV incidence from other interventions,
thus not allowing us to understand the effectiveness of these interven-
tions in isolation [67,71]. Second, comparability across studies was diffi-
cult since parameters, settings, and assumptions vary. Unless studies
present cost-effectiveness estimates using the same assumptions, base
year, time horizon, and discount rate, we should take caution when
comparing study estimates.
Third,manyof the cost-effectiveness studies offer evidence for a spe-
cific intervention in a number of scenarios, but few address the potential
effects of an intervention in scenarios outside the scope of the study.
Thismakes it difficult to generalize a study's results to other country set-
tings, creating an obstacle for policy makers in determining how and
when a single intervention is themost cost-effective for a specific coun-
try. The limited geographic coverage among the studies additionally
does not allow for broad generalizability. South Africa was the setting
in 24 of the 60 studies (40%) and just three countries (South Africa,
Zambia, and, Malawi) comprise over 60% of the studies.
Fig. 7. Cost-effectiveness measures of structural interventions. Data points reflect the measures from structural intervention studies reporting cost per HIV infection averted (above) and
cost per DALY averted (below). Points represent study-specific cost-effectiveness estimates; error bars represent estimate ranges, if provided in study results.
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Table 3
CHEERS quality assessment, by intervention type.
1 2 3 4 5 6 7 8 9 10 11a 11b 12 13a 13b 14 15 16 17 18 19 20a 20b 21 22 23 24
Binagwaho et al. (2010) [15] Y⁎ Y Y Y Y Y Y Y Y N⁎ Y N/A⁎ N/A N/A Y N P⁎ Y N Y Y N/A Y N/A Y N Y
Njeuhmeli et al. (2011) [16] N Y Y Y Y Y N Y Y Y N/A Y N/A N/A Y N Y Y N Y Y N/A Y N/A Y Y Y
Uthman et al. (2011) [17] Y Y Y Y Y Y Y Y P Y N/A N N/A N/A Y Y Y Y Y Y Y N/A Y N/A Y N N
Duffy et al. (2013) [18] Y Y Y Y Y Y N Y Y N P N/A N/A Y N/A Y N Y P P Y N/A N/A N/A Y N Y
Menon et al. (2014) [19] N Y Y Y Y N N P Y P N N/A N/A Y N/A Y Y Y N Y Y N N/A N/A Y Y Y
Awad et al. (2015) [20] N Y Y Y Y N Y Y Y Y N/A Y N/A N/A Y N Y Y Y N Y N/A Y N/A Y Y Y
Awad et al. (2015) [21] N Y Y Y Y Y Y Y Y Y N/A Y N/A N/A Y N Y Y Y Y Y N/A Y N/A Y Y Y
Haacker et al. (2016) [22] Y Y Y Y Y N Y N Y P N/A Y N/A Y Y Y Y Y Y N Y N/A Y N/A Y Y Y
Kripke et al. (2016) [23] P P Y Y Y P Y Y P N N/A N P N/A Y N Y P N N Y N/A P Y Y Y Y
Kripke et al. (2016) [24] Y P Y Y Y N Y Y P Y N/A Y N/A N/A Y P P P P P P N/A Y N/A Y Y Y
Kripke et al. (2016) [25] N P Y P P N N P P P N/A N N/A N/A Y P Y P P N Y N/A Y Y Y Y Y
Kripke et al. (2016) [26] N P Y Y Y N P Y P Y N/A N N/A N/A Y P Y Y N N P N/A Y Y Y Y Y
Kripke et al. (2016) [27] N P P Y Y N N Y P Y N/A P N/A N/A Y Y P P Y N Y N/A Y Y Y Y Y
Njeuhmeli et al. (2016) [28] P P Y P Y N Y Y P Y N/A P N/A N/A Y P Y P P N Y N/A P N/A Y Y Y
PrEP
Pretorius et al. (2010) [29] Y Y Y Y Y N Y P N P Y N/A N N/A P N Y Y Y Y P N/A Y N/A Y Y Y
Hallett et al. (2011) [30] N Y Y Y P N Y N P Y N/A Y N N/A P N Y Y Y Y Y N/A P N/A Y Y Y
Cremin et al. (2013) [31] N P Y Y Y Y Y Y P P N/A Y N/A N/A Y Y Y Y Y Y P N/A Y N/A Y Y Y
Nichols et al. (2013) [32] Y Y Y Y Y P Y P P P N/A P N N/A P N Y Y Y Y Y N/A Y N/A Y Y Y
Verguet et al. (2013) [33] N Y Y P Y N Y Y N P N/A Y Y N/A P N Y Y Y Y Y N/A Y N/A Y N Y
Alistar et al. (2014) [34] Y Y Y P Y N Y Y P P N/A Y N N/A Y N Y Y Y Y Y N/A Y N/A Y Y Y
Nichols et al. (2014) [35] Y Y Y Y Y N Y Y P P N/A Y N N/A P N P Y Y P Y N/A P N/A Y Y Y
Cremin et al. (2015a) [36] N N Y Y Y Y Y Y P P Y N/A N/A N/A Y N Y Y P P Y N/A N N/A P Y Y
Cremin et al. (2015b) [37] Y Y Y Y Y Y Y Y P P N/A Y N/A N/A P N Y Y N Y Y N/A N N/A P Y Y
Ying et al. (2015) [38] Y Y Y Y Y Y Y Y P P Y N/A N N/A Y Y Y N P N P N/A N N/A Y Y Y
Glaubius et al. (2016) [39] Y Y Y Y Y Y Y Y P P N/A Y N/A N/A Y Y P Y Y Y Y N/A Y N/A Y Y Y
Walensky et al. (2016) [40] Y Y Y Y Y Y Y Y P P N/A P N/A N/A Y Y Y Y Y Y Y N/A Y N/A Y Y Y
Cremin et al. (2017) [41] N Y Y Y Y Y Y Y P P N/A Y N/A N/A Y P Y Y Y P P N/A P N/A Y Y Y
TasP
Barnighausen et al. (2012) [42] P P Y P Y N Y Y Y P N/A Y N/A N/A P N Y Y Y N Y N/A Y N/A Y N Y
Granich et al. (2012) [43] Y Y Y Y Y P Y Y Y Y N/A P Y N/A Y Y Y Y Y Y Y N/A Y N/A Y Y Y
Smith et al. (2015) [44] Y Y Y Y Y Y Y Y P Y N/A Y P Y N/A P Y Y Y P Y N/A Y N/A Y Y Y
Bershteyn et al. (2016) [45] N Y Y P Y N P P P N N/A N N N/A P N Y Y Y N Y N/A Y Y Y Y Y
Ying et al. (2016) [46] N P Y Y Y Y Y P P P Y N/A N Y N/A Y P Y Y N Y Y N/A N/A Y Y Y
PMTCT
Halperin et al. (2009) [47] N Y Y P P Y P N N Y N/A Y N/A N/A Y N N Y Y Y Y N/A N N/A Y Y Y
Nakakeeto et al. (2009) [48] P P P P P Y Y P P Y N/A Y N/A N/A Y Y Y Y N Y P N/A P N/A Y Y N
Orlando et al. (2010) [49] Y Y Y Y Y Y Y Y Y Y Y N/A Y N/A Y Y N P P P Y N N/A N/A Y P N
Robberstad et al. (2010) [50] Y Y Y Y Y N Y N P Y N N/A Y N/A N N P Y P P P Y N/A N/A Y Y N
Shah et al. (2011) [51] Y P Y p Y Y Y Y Y N/A N/A Y Y N/A Y Y Y Y Y Y Y N/A Y N/A Y Y Y
Kuznik et al. (2012) [52] Y Y Y Y Y Y Y Y Y Y N/A N Y N/A Y Y Y Y Y Y Y Y N/A N/A Y N Y
Binagwaho et al. (2013) [53] Y P Y Y Y Y Y Y Y Y N/A Y N/A N/A Y P N Y Y Y P N/A Y Y Y N N
Fasawe et al. (2013) [54] Y Y Y Y Y Y Y Y P Y N/A Y P N/A Y P Y Y Y Y Y N/A Y N/A Y P N
Maredza et al. (2013) [55] Y Y Y Y Y Y Y Y Y Y N/A Y Y N/A Y Y P Y Y Y Y N/A Y N/A Y N N
Gopalappa et al. (2014) [56] N Y Y Y P N Y Y P P N/A Y N/A N/A Y P Y Y P Y Y N/A N N/A Y Y Y
Ishikawa et al. (2014) [57] P Y Y Y Y Y Y Y P Y N/A P Y N/A Y N Y Y Y Y Y N/A Y N/A Y Y Y
Yu et al. (2014) [58] Y Y Y Y Y N Y Y P Y N/A Y Y N/A Y Y Y Y Y Y Y N/A Y N/A Y Y Y
Zulliger et al. (2014) [59] Y Y P Y Y N Y Y Y Y Y N/A Y Y N/A Y N Y P Y Y Y N/A N/A Y Y Y
Price et al. (2016) [60] Y Y Y Y Y Y Y P P Y N/A Y Y N/A Y Y P Y Y Y Y N/A Y N/A Y Y Y
Tweya et al. (2016) [61] Y Y Y Y Y N Y P P Y N/A Y N N/A P P Y Y Y Y Y N/A Y N/A Y Y Y
Other biomedical
Verguet et al. (2010) [62] Y Y Y Y P N Y Y Y Y N/A Y Y Y Y Y Y Y Y Y Y N/A Y N/A Y N Y
Williams et al. (2011) [63] N P Y N N N P P N Y Y N/A P N/A Y N Y Y Y N Y N/A N N/A Y Y Y
Long et al. (2013) [64] Y Y Y Y Y N P Y N Y N/A Y Y Y N P Y Y Y Y Y N/A Y N/A Y Y Y
Mbah et al. (2013) [65] Y P Y Y Y Y Y P Y Y N/A Y N/A Y Y Y Y Y Y Y Y N/A Y N/A P Y Y
Terris-Prestholt et al. (2014) [ 66] Y Y Y Y Y Y Y Y P Y N/A Y N Y Y Y Y Y Y Y Y N/A Y N/A Y Y Y
Mvundura et al. (2015) [67] Y Y Y N Y N Y Y N Y N/A P N/A N/A Y Y Y Y N P Y N/A N N/A Y P Y
Moodley et al. (2016) [68] Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y Y N/A Y N/A Y Y Y
Moodley et al. (2016) [69] Y Y Y Y Y Y Y Y Y Y Y N/A N/A N/A Y Y Y Y Y Y Y N/A Y N/A Y Y Y
Wall et al. (2018) [70] N P Y P Y Y Y Y Y Y P N/A N/A Y N/A N N P Y P Y Y Y N/A Y Y Y
Behaviour Change
Enns et al. (2011) [71] Y Y Y Y Y Y Y Y P P N/A Y N/A N/A P N Y Y Y Y Y N/A Y N/A Y Y Y
Structural
Fieno et al. (2014) [72] N N P Y Y N P P N Y Y N/A N/A Y N/A N P Y P Y Y N N/A N/A Y N Y
Remme et al. (2014) [73] N P Y Y Y Y Y P P Y P N/A Y Y N/A Y Y Y Y Y Y Y N/A N/A Y Y Y
Rutstein et al. (2014) [74] Y P Y Y Y Y Y P N Y Y N/A N/A Y N/A Y Y Y Y Y Y Y N/A N/A Y Y N
Abbreviations: Y = item completely fulfilled; P = item partially fulfilled; N = item not fulfilled; N/A = item not applicable to the study
Item Checklist: 1. Title; 2. Abstract; 3. Introduction 4. Target Population; 5. Setting and Location; 6. Study Perspective; 7. Comparators; 8. Time Horizon; 9. Discount Rate; 10. Choice of
health outcomes; 11a. Measurement of effectiveness (single study-based estimates); 11b. Measurement of effectiveness (synthesis-based estimates); 12. Measurement of performance
based outcomes; 13a. Estimating Resources and Costs (single study-based economic evaluation); 13b. Estimating Resources and Costs (model-based economic evaluation); 14. Currency,
Price, Conversion; 15. Model Choice; 16. Assumptions; 17. Analytical Methods; 18. Study Parameters; 19. Incremental Costs and Outcomes; 20a. Characterizing Uncertainty (single study-
based economic evaluation); 20b. Characterizing Uncertainty (model-based economic evaluation); 21. Heterogeneity; 22. Study Findings; 23. Funding; 24. Conflicts of Interest
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Lastly, this review is not immune to publication bias. Studies that do
not demonstrate interventions as cost-effective are less likely to be sub-
mitted to peer-reviewed journals or to be published by journals [83]. It is
possible that some cost-effectiveness results of current HIV interventions
are not available to key policy makers, which poses a large problem. De-
spite the aforementioned limitations, this review included studies of
good quality, highlighting the strength of the available evidence.
The large number of studies included in this review reflects the in-
creasing importance of considering cost-effectiveness as a factor in
implementing HIV prevention interventions in sub-Saharan Africa. The
studies demonstrated intervention cost-effectiveness under a variety
of scenarios and emphasized interventions targeting high-risk popula-
tions. In contrast to the 2009 Galarraga review, which concluded that
sufficient cost-effectiveness data did not exist to inform large-scale de-
cision making, the results from emergent, more robust and varied cost-
ing studiesmay serve as an aid to inform evidence-based decisions. Key
stakeholders, such as international donors and government agencies,
should consider cost-effectiveness results and affordability when devel-
oping national guidelines and protocols for HIV prevention tomaximize
prevention impact under resource constraints. However, important
gaps in the research persist: a lack of focus on vulnerable populations
remains an important concern in this region, and additional studies
that discuss the cost-effectiveness of different combinations of interven-
tions are needed to reflect the reality of HIVprograms in this region [84].
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